|
1
|
Rodan GA and Fleisch HA: Bisphosphonates:
mechanisms of action. J Clin Invest. 97:2692–2696. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hortobagyi GN, Theriault RL, Porter L,
Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and
Knight RD: Efficacy of pamidronate in reducing skeletal
complications in patients with breast cancer and lytic bone
metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J
Med. 335:1785–1791. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hughes DE, Wright KR, Uy HL, Sasaki A,
Yoneda T, Roodman GD, Mundy GR and Boyce BF: Bisphosphonates
promote apoptosis in murine osteoclasts in vitro and in vivo. J
Bone Miner Res. 10:1478–1487. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jagdev SP, Coleman RE, Shipman CM, Rostami
HA and Croucher PI: The bisphosphonate, zoledronic acid induces
apoptosis of breast cancer cells: evidence for synergy with
paclitaxel. Br J Cancer. 84:1126–1134. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crohns CA, Untch M and Konecny G:
Different bisphosphonates have direct cytotoxic effects on three
breast cancer cell lines and fresh breast cancer tumor tissue. Proc
Am Soc Clin Oncol. 20:abs. 20052001.
|
|
6
|
Santini D, Vespasiani Gentilucci U,
Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S and
Tonini G: The antineoplastic role of bisphosphonates: from basic
research to clinical evidence. Ann Oncol. 14:1468–1476. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teronen O, Heikkila P, Konttinen YT,
Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P and Sorsa T:
MMP inhibition and down-regulation by bisphosphonates. Ann NY Acad
Sci. 878:453–465. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paterson AH: The potential role of
bisphosphonates as adjuvant therapy in the prevention of bone
metastases. Cancer. 88:3038–3046. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sasaki A, Boyce BF, Story B, Wright KR,
Chapman M, Boyce R, Mundy GR and Yoneda T: Bisphosphonate
risedronate reduces metastatic human breast cancer burden in bone
in nude mice. Cancer Res. 55:3551–3557. 1995.PubMed/NCBI
|
|
10
|
Van der Pluijm G, Vloedgraven H, Van Beek
E, Van der Wee-Pals L, Lowik C and Papapoulos S: Bisphosphonates
inhibit the adhesion of breast cancer cells to bone matrices in
vitro. J Clin Invest. 98:698–705. 1996.
|
|
11
|
Diel IJ, Solomayer EF, Costa SD, Gollan C,
Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new
metastases in breast cancer with adjuvant clodronate treatment. N
Engl J Med. 339:357–363. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diel IJ, Solomayer EF, Gollan C, Schutz F
and Bastert G: Bisphosphonates in the reduction of metastases in
breast cancer - results of the extended follow-up of the first
study population. Proc Am Soc Clin Oncol. 19:abs. 3142000.
|
|
13
|
Jaschke A, Bastert G, Solomayer EF, Costa
S, Schuetz F and Diel IJ: Adjuvant clodronate treatment improves
the overall survival of primary breast cancer patients with
micrometastases to bone marrow - a longtime follow-up. J Clin
Oncol. 22:abs. 5292004.
|
|
14
|
Powles T, Paterson S, Kanis JA, McCloskey
E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S,
Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen
J and Pylkkanen L: Randomized placebo-controlled trial of
clodronate in patients with primary operable breast cancer. J Clin
Oncol. 20:3219–3224. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Powles T, Paterson A, McCloskey E,
Kurkilahti M and Kanis J: Oral clodronate for adjuvant treatment of
operable breast cancer: results of a randomized, double-blind,
placebo-controlled multicenter trial. J Clin Oncol. 22:abs.
5282004.PubMed/NCBI
|
|
16
|
Saarto T, Blomqvist C, Virkkunen P and
Elomaa I: Adjuvant clodronate treatment does not reduce the
frequency of skeletal metastases in node-positive breast cancer
patients: 5-year results of a randomized controlled trial. J Clin
Oncol. 19:10–17. 2001.PubMed/NCBI
|
|
17
|
Saarto T, Vehmanen L, Blomqvist C and
Elomaa I: Ten-year follow-up of a randomized controlled trial of
adjuvant clodronate treatment in node-positive breast cancer
patients. J Clin Oncol. 22:abs. 5272004.PubMed/NCBI
|
|
18
|
Colleoni M, O’Neill A, Goldhirsch A,
Gelber RD, Bonetti M, Thurlimann B, Price KN, Castiglione-Gertsch
M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J,
Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M and
Rudenstam CM: Identifying breast cancer patients at high risk for
bone metastases. J Clin Oncol. 18:3925–3935. 2000.PubMed/NCBI
|
|
19
|
Goldhirsch A, Wood WC, Gelber RD, Coates
AS, Thurlimann B and Senn HJ: Progress and promise: highlights of
the international expert consensus on the primary therapy of early
breast cancer 2007. Ann Oncol. 18:1133–1144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Michiqami T, Wiliams P and Dallas M:
Bisphosphonate may increase metastases to soft tissue sites in
breast cancer and B-cell lymphoma. J Bone Miner Res. 12(Suppl 1):
s106abs 115. 1997.
|
|
21
|
Leyvraz S, Hess U, Flesch G, Bauer J,
Hauffe S, Ford JM and Burckhardt P: Pharmacokinetics of pamidronate
in patients with bone metastases. J Natl Cancer Inst. 84:788–792.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gnant M, Mlineritsch B, Schippinger W,
Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Kubista
E, Marth C and Greil R; on behalf of the ABCSG. Adjuvant ovarian
suppression combined with tamoxifen or anastrozole, alone or in
combination with zoledronic acid, in premenopausal women with
hormone-responsive, stage I and II breast cancer: First efficacy
results from ABCSG-12. J Clin Oncol. 26:abs. LBA 42008.
|
